Preliminary Results of Noninvasive Detection of TMPRSS2:ERG Gene Fusion in a Cohort of Patients With Localized Prostate Cancer

다국어 초록 (Multilingual Abstract)

Purpose: The aim of this study was to evaluate TMPRSS2:ERG fusion rates in tissue,urine, blood, and pubic hair samples in a cohort of patients with localized prostate cancer and to correlate these findings with various clinicopathological parameters.
Materials and Methods: A cohort of 40 patients undergoing radical prostatectomy for localized prostate cancer (RRP group) and 10 control patients undergoing prostate biopsy were enrolled between 2006 and 2008. Urine, pubic hair, and peripheral blood samples were obtained following prostatic massage before the needle biopsy or radical prostatectomy. Quantitative polymerase chain reaction analysis was performed on all collected samples.
Results: The patients’ mean age was 62.4 (±5.5) years. We observed higher expressions of TMPRSS2:ERG fusion in tissue, urine, and blood samples from the RRP group than in samples from the control group. Overall, the fusion was present in urine samples of 23 RRP patients (57.5%). To predict high-stage cancer (＞T3a), the Gleason score was the only significant factor in the logistic regression analysis (score, 10.579; p=0.001).
Quantitative evaluation of the gene fusion in tissue (Pearson r=0.36, p=0.011) and urine (Pearson r=0.34, p=0.014) samples had a significant positive correlation with the preoperative prostate-specific antigen level.
Conclusions: Urine sediments collected after prostatic massage appear to be a feasible noninvasive method of detecting TMPRSS2:ERG fusion. The Gleason score is the only significant factor to predict high-stage cancer (＞T3a). No correlation between TMPRSS2:ERG gene fusion status and tumor stage, Gleason grade, prostate-specific antigen level, or surgical margin status was observed.

참고문헌 (Reference)

1 Tomlins SA, "Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA" 3 : 94-72, 2011

2 Shah RB, "The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications" 16 : 145-153, 2009

3 Pettersson A, "The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis" 21 : 1497-1509, 2012

4 Saramäki OR, "TMPRSS2:ERG rearrangement is an independent marker of good prognosis in prostate cancer [abstract 730]" 7 : 253-, 2008

5 Demichelis F, "TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort" 26 : 4596-4599, 2007

6 Perner S, "TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer" 66 : 8337-8341, 2006

7 Rostad K, "TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis" 117 : 575-582, 2009

8 Fine SW, "TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features" 23 : 1325-1333, 2010

9 Lee K, "TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients" 76 : 1268.e7-1268.e13, 2010

10 Kumar-Sinha, "Recurrent gene fusions in prostate cancer" 8 : 497-511, 2008

11 Tomlins SA, "Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer" 310 : 644-648, 2005

12 Barwick BG, "Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts" 102 : 570-576, 2010

13 Leyten GH, "Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer" 2012

14 Hermans KG, "Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer" 15 : 6398-6403, 2009

15 Laxman B, "Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer" 8 : 885-888, 2006

16 Salagierski M, "Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion" 187 : 795-801, 2012

17 Rajput AB, "Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers" 60 : 1238-1243, 2007

18 Wang J, "Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer" 66 : 8347-8351, 2006

19 Attard G, "Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer" 27 : 253-263, 2008

20 Clark J, "Diversity of TMPRSS2-ERG fusion transcripts in the human prostate" 26 : 2667-2673, 2007

21 Mao X, "Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells" 10 : 467-473, 2008

22 Velaeti S, "Detection of TMPRSS2-ERG fusion gene in benign prostate hyperplasia" 8 : 614-, 2009

23 Randall VA, "Cultured dermal papilla cells from androgen-dependent human hair follicles (e.g. beard) contain more androgen receptors than those from nonbalding areas of scalp" 133 : 141-147, 1992

24 Young A, "Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden" 138 : 685-696, 2012

25 Jemal A, "Cancer statistics, 2010" 60 : 277-300, 2010

26 Killick E, "Beyond prostate-specific antigen: future biomarkers for the early detection and management of prostate cancer" 24 : 545-555, 2012